Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants

Thrombosis and Haemostasis

Volumn 89, Issue 2, 2003, Pages 208-212

  Regnault, Véronique ^a   Béguin, Suzette ^b   Wahl, Denis ^a,b,c   De Maistre, Emmanuel ^c   Hemker, H Coenraad ^b   Lecompte, Thomas ^a,b,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Acquired APC resistance; Lupus anticoagulant; Platelets; Thrombin activity

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; RECOMBINANT THROMBOMODULIN; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CALCIFICATION; CLINICAL ARTICLE; DRUG EFFECT; FLUOROMETRY; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

EID: 0037324197     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613433     Document Type: Article

References (19)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
2. Roubey RAS, Hoffman M. From Antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997; 350: 1491-3.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
4. 2-glycoprotein I to phospholipids. Thromb Haemost 2002; 88: 620-6.
5. Esmon NL, Smirnov MD, Safa O, Esmon CT. Lupus anticoagulants, thrombosis and the protein C system. Haematologica 1999; 84: 446-51.
6. Male C, Mitchell L, Julian J, Vegh P, Joshuan P, Adams M, David M, Andrew ME. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematous. Blood 2001; 97: 844-9.
7. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118: 577-83.
8. Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platleet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
9. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for identification of Lupus Anticoagulants. On behalf of the Subcomittee on Lupus Anticoagulants/Antiphospholipid antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-603.
10. Hezard N, Cornillet P, Droulle C, Gillot P, Potron G, Nguyen P, Factor V Leiden: Detection in whole blood by ASA PCR using additional mismatch in antepenultimate position. Thromb Res 1997; 88: 59-66.
11. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
12. Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: Monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 589-91.
13. Regnault V, De Maistre E, Gerschier C, Briquel ME, André E, Stolz JF, Lecompte T. A new fast one-step immunopreparation for activated protein C. Thromb Haemost 1995; 73: 1365.
14. Wielders S, Mukherjee M, Michiels J, Rijkers DTS, Cambus JP, Knedel RWC, Kakkar V, H. C.H, Béguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
15. Carson CW, Comp PC, Rezaie AR, Esmon NL, Esmon CT. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000; 27: 384-90.
16. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
17. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
18. Derksen RHWM, De Groot PG. Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anticoagulation? J Autoimmun 2000; 15: 255-9.
19. Wahl DG, Bounameaux H, De Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arch Intern Med 2000; 160: 2042-8.